Payment overview · 2025
General Payments
$352.59
14 reported records · 2 companies
Healthcare provider profile · identity verified
Cari Beth Page, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOUTH PITTSBURG, TN · NPI 1467423947
Verified facts
What the public records show
CMS Open Payments records show Cari Beth Page, MD received $352.59 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $198.73 | 56.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.86 | 43.6% | 8 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.59 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $198.73 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $135.16 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.27 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.85 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 101 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
90 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 610 | 151 |
| Metformin Hcl | Metformin Hcl | 443 | 107 |
| Lisinopril | Lisinopril | 427 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 407 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 372 | 97 |
| Omeprazole | Omeprazole | 349 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 241 | 39 |
| Meloxicam | Meloxicam | 233 | 51 |
| Gabapentin | Gabapentin | 218 | 45 |
| Furosemide | Furosemide | 215 | 65 |
| Potassium Chloride | Potassium Chloride | 211 | 56 |
| Tramadol Hcl | Tramadol Hcl | 207 | 37 |
| Carvedilol | Carvedilol | 206 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 44 |
| Trazodone Hcl | Trazodone Hcl | 176 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 173 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 43 |
| Alprazolam | Alprazolam | 157 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 58 |
| Montelukast Sodium | Montelukast Sodium | 146 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 34 |
| Losartan Potassium | Losartan Potassium | 138 | 41 |
| Eliquis | Apixaban | 130 | 25 |
| Warfarin Sodium | Warfarin Sodium | 129 | 16 |
| Prednisone | Prednisone | 126 | 68 |
| Celecoxib | Celecoxib | 122 | 39 |
| Simvastatin | Simvastatin | 122 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 121 | 38 |
| Januvia | Sitagliptin Phosphate | 117 | 19 |
| Pregabalin | Pregabalin | 115 | 21 |
| Famotidine | Famotidine | 114 | 26 |
| Glimepiride | Glimepiride | 110 | 31 |
| Sertraline Hcl | Sertraline Hcl | 110 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 29 |
| Mounjaro | Tirzepatide | 101 | 20 |
| Buspirone Hcl | Buspirone Hcl | 94 | 24 |
| Valsartan | Valsartan | 94 | 21 |
| Jardiance | Empagliflozin | 92 | 19 |
| Trulicity | Dulaglutide | 90 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 24 |
| Estradiol | Estradiol | 87 | 25 |
| Mirtazapine | Mirtazapine | 86 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 19 |
| Amoxicillin | Amoxicillin | 81 | 66 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 22 |
| Ezetimibe | Ezetimibe | 78 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 20 |
| Linzess | Linaclotide | 70 | 21 |
| Naproxen | Naproxen | 70 | 14 |
| Bupropion Xl | Bupropion Hcl | 69 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 19 |
| Farxiga | Dapagliflozin Propanediol | 68 | 11 |
| Baclofen | Baclofen | 67 | 15 |
| Clonazepam | Clonazepam | 66 | 16 |
| Synthroid | Levothyroxine Sodium | 66 | 14 |
| Diazepam | Diazepam | 64 | 12 |
| Methocarbamol | Methocarbamol | 64 | 18 |
| Spironolactone | Spironolactone | 63 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Allopurinol | Allopurinol | 61 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 59 | suppressed |
| Lansoprazole | Lansoprazole | 58 | 13 |
| Ozempic | Semaglutide | 58 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 14 |
| Xarelto | Rivaroxaban | 57 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Nabumetone | Nabumetone | 53 | 11 |
| Aripiprazole | Aripiprazole | 52 | 11 |
| Cephalexin | Cephalexin | 50 | 35 |
| Azithromycin | Azithromycin | 48 | 37 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 16 |
| Fluconazole | Fluconazole | 46 | 29 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Glipizide | Glipizide | 42 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Nystatin | Nystatin | 36 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 14 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 12 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 12 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.59 · 14 records | Novo Nordisk Inc | MOUNJARO, Ozempic, Rybelsus, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error